Evidence map›Paper›PMID 42067571›Full record

ArticleScientific reports2026

PBPK modeling predicts rilzabrutinib dose adjustments using BTK occupancy for CYP3A4 interactions and hepatic impairment.

Xiaoping Yan, Zhiwei Yan, Lirong Xiao, Dehu Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiaoping YanZhangzhou Health Vocational College, Fujian, 363000, China. zw_yxp8157@163.com.
Zhiwei YanZhangzhou People's Hospital, Fujian, 363000, China.
Lirong XiaoThe First Affiliated Hospital of Fujian Medical University, Fujian, 350000, China.
Dehu LuPeking University International Hospital, Beijing, 102206, China. 13426399153@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to develop and validate a population-based physiologically-based pharmacokinetic (PBPK) model for the Bruton's tyrosine kinase inhibitor rilzabrutinib (RIL) to predict its pharmacokinetic (PK) and BTK occupancy (BO) profiles under various scenarios, including drug-drug interactions (DDIs) with CYP3A4 modulators and in patients with hepatic impairment. A PBPK model for RIL was constructed using PK data, BO parameters, and interaction parameters. The model was validated against clinical PK parameters (AUC and C

Indexed as

Agammaglobulinaemia Tyrosine KinaseCytochrome P-450 CYP3ALiver DiseasesModels, BiologicalProtein Kinase InhibitorsPyrimidinesCytochrome P-450 CYP3A InhibitorsDrug InteractionsHeterocyclic Compounds, 2-RingHumansNitrilesPiperazinesAgammaglobulinaemia Tyrosine KinaseBTK protein, humanCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsHeterocyclic Compounds, 2-RingNitrilesPiperazinesProtein Kinase InhibitorsPyrimidinesrilzabrutinibBTK occupancyDDIsHepatic impairmentPBPK modelRilzabrutinib

Identifiers

PMID42067571
PMCPMC13323760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.